The life sciences industry has become a priority target for shareholder plaintiff’s lawyers. According to Cornerstone Research’s 2015 annual study, securities class action filings against pharmaceutical and medical device companies have risen for three consecutive years and accounted for approximately 32 percent of all securities class action filings nationwide during 2015. Many of these cases involve adverse U.S. Food and Drug Administration decisions, clinical holds, unfavorable study results and undisclosed safety or efficacy problems. Fortunately, pharmaceutical and medical device companies can mitigate the risk of securities litigation by implementing prudent disclosure practices and by proactively reviewing their disclosures with outside counsel.
Read more ...
Recommended changes to improve Australia’s Medical Cannabis laws
On 5 September 2019, Professor John McMillan AO’s Final Report (Report) on the operation of the Narcotic Drugs Act 1967 (ND Act) was tabled in Parliament. Section 26A of the ND Act required the Minster to cause a review of the operation of the ND Act to be undertaken.